antibodies against cd13  (Proteintech)

Journal: bioRxiv

Article Title: Blockade of VCAM1 or VLA4 preserves cerebrovasculature and prevents cognitive decline late after stroke

doi: 10.1101/2025.06.25.661593

Figure Lengend Snippet: A) Total vessel length in the peri-infarct cortex after 3 weeks of chronic isotype control (Stroke-α-IC) or anti-VCAM1 (Stroke-α-VCAM1) antibody treatment, using endothelial staining for CD31 to define vasculature. B) Representative confocal images and (C) quantification of pericyte (CD13+) coverage of CD31+ vasculature in the peri-infarct cortex or contralateral cortical region of stroked mice treated with isotype control (Stroke-α-IC) or anti-VCAM1 (Stroke-α-VCAM1) antibody. D) Total vessel length in the peri-infarct cortex after 3 weeks of chronic isotype control (Stroke-α-IC) or anti-VLA4 (Stroke-α-VLA4) antibody treatment. E) Representative confocal images and (F) quantification of pericyte (CD13+) coverage of CD31+ vasculature in the peri-infarct cortex or contralateral cortical region of stroked mice treated with isotype control (Stroke-α-IC) or anti-VLA4 (Stroke-α-VLA4) antibody. Scale bar, 20 µM; Statistics, Student’s t test or 2-way ANOVA with Tukey’s post hoc test for group comparisons; Error bars, mean ± SEM; *p < 0.05; **p < 0.01.

Article Snippet: Primary antibodies were used against CD13 (1:500; Bio-Rad, MCA2183GA), CD31 (1:200; Novus Biologicals, AF3628 or 1:300, BD Biosciences, 550274), fibrinogen (1:1000; DAKO, A0080), and GFAP (1:1000; Abcam, Ab4674).

Techniques: Control, Staining